Accessibility: Skip TopNav
Figure 2: Waterfall Plot for Patients in the 200 mg Dose Cohort of the CPI-818 Phase 1/1b Clinical Trial for T Cell Lymphoma.
The plot shows the best percent change in tumor volume in the evaluable patients from the same group shown in Figure 1.
Format
JPEG
Source
Corvus Pharmaceuticals, Inc.
Downloads
Original
Large
Medium
Small